1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Procyon Corporation

Procyon Corporation

PCYN
Procyon CorporationUS flagOther OTC
0.20
USD
- -
- -
1.63MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.35
0.34
0.35
0.34
0.43
0.5
0.5
0.52
0.54
0.58
0.6
0.58
- -
0.61
Basic EPS, GAAP
0.01
-0.02
- -
-0.03
0.01
- -
-0.03
- -
0.01
0.08
-0.03
-0.01
- -
-0.04
Free Cash Flow per Basic Share
0.05
- -
-0.02
-0.06
-0.01
0.02
- -
- -
0.02
0.03
-0.06
- -
- -
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.26
-0.28
-0.27
0.25
0.26
0.26
0.23
0.24
0.25
0.34
0.31
0.3
- -
0.26
Tangible Book Value per Share
0.29
0.27
0.28
0.25
0.26
0.26
0.23
0.24
0.25
0.34
0.31
0.31
- -
0.27
Basic Weighted Avg Shares
8
8
8
8
8
8
8
8
8
8
8
8
- -
8
Sales/Revenue/Turnover
3
3
3
3
3
4
4
4
4
5
5
5
5
5
Operating Margin (%)
8.26
-0.46
2.3
-12.32
-3
0.75
3.16
2.32
3.53
4.8
-4.9
-2.08
-4.65
-4.65
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
Effective Tax Rate (%)
40.82
- -
65.75
- -
42.38
57.3
300.35
72.59
30.24
5.38
- -
- -
- -
- -
Profit Margin (%)
4.59
-3.79
0.83
-7.87
3.18
0.31
-6.36
0.65
2.58
14.71
-4.33
-1.07
-6.84
-6.84
Working Capital
1
1
1
1
1
1
1
1
2
2
2
2
2
2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
Total Equity
2
2
2
2
2
2
2
2
2
3
3
3
2
2
Return on Invested Capital (%)
5.23
- -
0.95
- -
-2.58
0.55
-11.78
1.3
4.84
7.11
- -
- -
- -
- -
Return on Capital (%)
-7.65
- -
-1.14
- -
4.85
0.58
-11.91
1.34
5.08
23.22
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
4.39
1.21
-13.62
0.54
4.82
28.61
-8.68
-2.7
-13.65
-13.65

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
1
2
2

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'24
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
1
- -
1
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
- -
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.33%
3.26%
-12.62%
Free Cash Flow
10.19%
113.73%
260.99%
Net Income, GAAP
-233.54%
240.94%
578.95%
Sales/Revenue/Turnover
6.09%
3.61%
6.35%
Total Cash Common Dividend
- -
- -
-268.63%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1
1
1
1
5
2023
1
1
1
1
5
2024
1
1
1
1
5

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
-0.01
-0.01
- -
-0.03
2023
- -
- -
- -
- -
-0.01
2024
- -
-0.03
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Justice W. Anderson
Full Time Employees
19
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
1300 South Highland Avenue Clearwater FL United States of America 33756
IPO Date
Dec 11, 1996
CIK
0000812306
Website
procyoncorp.com
Similar Companies
Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF)
Hyundai Pharmaceutical Co., Ltd. (004310.KS)
Cyclo Therapeutics, Inc. (CYTH)
Lee's Pharmaceutical Holdings Limited (0950.HK)
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ)
Sproutly Canada Inc. (SPR.CN)
Business
Procyon Corporation (Ticker: PCYN) develops and commercializes innovative technologies for the biotechnology and life sciences sectors. The company offers a portfolio of core products and services including proprietary diagnostic assays for early disease detection; advanced molecular imaging platforms; custom contract research services for pharmaceutical clients; and AI-driven data analytics tools for genomic sequencing, all designed to accelerate drug discovery and personalized medicine. Procyon operates primarily in North America and Europe, targeting pharmaceutical companies, research institutions, and clinical laboratories as key customers. Founded in 2012 and headquartered in San Diego, California, the company maintains strategic subsidiaries focused on regulatory compliance and international distribution. In the past year, Procyon announced a major strategic alliance with a leading global pharmaceutical firm to co-develop next-generation cancer therapeutics; completed a $75 million Series C funding round led by prominent venture capital investors to fuel expansion into Asia-Pacific markets; and launched its flagship ProcyonGenix AI platform, marking a shift toward integrated digital health solutions.